SCHEMBL29420832

SCHEMBL29420832

CC(C)(C)OC(=O)N(c1ccc(C(F)(F)F)cc1)c1ncc(Br)nc1C#N

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ NR1H3 Q13133 1/20 0.32
▸ MT-CO2 P00403 1/20 0.31
▸ HDAC3 O15379 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC2 Q92769 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ LIPE Q05469 3/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ MMP2 P08253 1/20 0.31
▸ CACNA1G O43497 1/20 0.31
▸ CACNA1B Q00975 1/20 0.31
▸ CACNA1C Q13936 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ XDH P47989 1/20 0.30
▸ SSTR4 P31391 1/20 0.30
▸ AR P10275 1/20 0.30
▸ VNN1 O95497 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22931775 1.00 RXRA (0.32) RXRANR1H2NR1H3MT-CO2HDAC3
SCHEMBL22931772 0.90 LIPE (0.37) RXRANR1H2NR1H3MT-CO2LIPE
SCHEMBL29806156 0.90 LIPE (0.37) RXRANR1H2NR1H3MT-CO2LIPE
SCHEMBL22932341 0.80 XDH (0.33) RXRANR1H2NR1H3MT-CO2LIPE
SCHEMBL22932332 0.80 BCHE (0.34) CACNA1BCACNA1CAR
SCHEMBL22931787 0.78 MT-CO2 (0.37) RXRANR1H2NR1H3MT-CO2LIPE
SCHEMBL22931784 0.77 TRPM8 (0.33) RXRANR1H2NR1H3ALDH1A1AR
SCHEMBL22931811 0.75 MT-CO2 (0.35) RXRANR1H2NR1H3MT-CO2LIPE
SCHEMBL22931813 0.74 MT-CO2 (0.33) RXRANR1H2NR1H3MT-CO2LIPE
SCHEMBL22931809 0.74 KDM4E (0.40) RXRANR1H2NR1H3MT-CO2LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003983-A1 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER Basilea Pharmaceutica International AG (CH) 2022-06-01 — — EP disclosed
CN-114174291-A 1,2, 4-oxadiazol-5-one derivatives for the treatment of cancer 巴斯利尔药物国际股份公司 2022-03-11 — — CN disclosed
Send feedback